Loading...
Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases
In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutrit...
Na minha lista:
| Udgivet i: | Reumatologia |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4967983/ https://ncbi.nlm.nih.gov/pubmed/27504026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/reum.2016.61217 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|